Compare MPX & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPX | PLYX |
|---|---|---|
| Founded | 1965 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.2M | 262.3M |
| IPO Year | 2000 | N/A |
| Metric | MPX | PLYX |
|---|---|---|
| Price | $7.44 | $5.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 33.3K | ★ 2.0M |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 7.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $244,419,000.00 | N/A |
| Revenue This Year | $13.72 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.13 | ★ N/A |
| Revenue Growth | ★ 3.32 | N/A |
| 52 Week Low | $6.83 | $2.20 |
| 52 Week High | $10.08 | $8.15 |
| Indicator | MPX | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 52.51 |
| Support Level | $6.83 | $2.37 |
| Resistance Level | $9.16 | $7.43 |
| Average True Range (ATR) | 0.17 | 1.11 |
| MACD | 0.07 | 0.22 |
| Stochastic Oscillator | 78.38 | 59.79 |
Marine Products Corp is a manufacturer of fiberglass motorized boats distributed and marketed through its independent dealer network. The company's only operating segment is Powerboat Manufacturing Business. It operates in the powerboat manufacturing business segment in Nashville, Valdosta, and Georgia. Its product offerings include Chaparral sterndrive, outboard pleasure boats, and Robalo outboard sport fishing boats. The company offers its products to the family recreational markets through its Chaparral brand and to the sportfishing market through its Robalo brand.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.